The Fate of Periprosthetic Joint Infection Following Megaprosthesis Reconstruction

Kamolsak Sukhonthamarn1,2, Timothy L Tan1, John Strony1

  • 1Rothman Orthopaedic Institute at Thomas Jefferson University, Philadelphia, Pennsylvania.

JB & JS Open Access
|November 29, 2021
PubMed
Abstract

Insights

Periprosthetic joint infection (PJI) rates are high after megaprosthesis reconstruction, with a significant portion of patients experiencing treatment failure. Debridement, antibiotics, and implant retention (DAIR) may be a viable option for some, but further research is needed.

Area of Science:

  • Orthopedic surgery
  • Infectious disease

Background:

  • Megaprostheses are used for massive bone loss or periprosthetic fractures.
  • Periprosthetic joint infection (PJI) is a challenging complication following megaprosthesis reconstruction.
  • Outcomes of PJI management in megaprosthesis patients are not well-defined.

Purpose of the Study:

  • To investigate the clinical course and outcomes of PJI in patients with megaprostheses.
  • To identify challenges and success rates of different management strategies for PJI in this population.

Main Methods:

  • Retrospective review of 219 patients undergoing non-oncologic megaprosthesis replacement.
  • Analysis of 38 patients (17.4%) who developed PJI.
  • Kaplan-Meier survival analysis and log-rank testing were used to evaluate outcomes.

Main Results:

  • The overall survival rate at 2 years post-PJI was 65.1%.
  • Mortality rate was 15%, with high rates of salvage procedures including amputation (18%).
  • Debridement, antibiotics, and implant retention (DAIR) was the primary surgical approach (82%).

Conclusions:

  • PJI occurs at a high rate (17%) after megaprosthesis reconstruction.
  • PJI management in these patients is difficult, with a 1 in 3 treatment failure rate.
  • DAIR may be a suitable strategy for some patients, but larger cohorts are needed to determine predictors of failure.